Japanese Sanofi To Quit Marketing Agreements For Nine Drugs (Japan)
This article was originally published in PharmAsia News
Executive SummarySanofi-Aventis KK, the French drug maker's Japanese unit, has decided to end its marketing partnerships and handle its own sales of flagship drugs in Japan. The firm's president said the change in strategy is part of its effort to double the 2005 Japanese sales level next year. The marketing partnerships include Chugai Pharmaceutical, handling seven drugs, which is to be canceled at the end of this year. Other partnerships are with Amoban for a sleep-disorder treatment, and Menamin for an anti-inflammatory painkiller, and they are to be ended in January. (Click here for more - may require subscription
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.